Gemtuzumab ozogamicin, Antibody Drug Conjugate  Broad approval covering front-line & relapse settings

Gemtuzumab ozogamicin, Antibody Drug Conjugate Broad approval covering front-line & relapse settings

hematologydebates

1 year
58 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Amer M Zeidan, MBBS, Gemtuzumab ozogamicin, Antibody Drug Conjugate Broad approval covering front-line & relapse settings at Imedex Great Debates 2018
Up Next Autoplay
Trends in Breast Cancer Death Rates
Trends in Breast Cancer Death Rates
Category: Breast Cancer
0 Views
Cancer-News 30 minutes
Breast Cancer Trends in U.S.
Breast Cancer Trends in U.S.
Category: Breast Cancer
0 Views
Cancer-News 34 minutes
What Happens When You Have An ATRX Deletion?
What Happens When You Have An ATRX Deletion?
Category: Kidney Cancer
0 Views
Mount Sinai Health System 41 minutes
Neuroblastoma in Older Children May Respond to Tazemetostat
Neuroblastoma in Older Children May Respond to Tazemetostat
Category: Kidney Cancer
1 Views
Mount Sinai Health System 1 hour
Lower Costs in Breast Cancer: How This Affects Treatment
Lower Costs in Breast Cancer: How This Affects Treatment
Category: Breast Cancer
0 Views
ONeal Comprehensive Cancer Center 1 hour
When Can This Be Used In Clinical Practice?
When Can This Be Used In Clinical Practice?
Category: Other
2 Views
Baylor College of Medicine 2 days
New Testing for Thyroid Cancer
New Testing for Thyroid Cancer
Category: Other
4 Views
Baylor College of Medicine 2 days
Lower Costs for Patients in Metastatic Breast Cancer
Lower Costs for Patients in Metastatic Breast Cancer
Category: Breast Cancer
15 Views
ONeal Comprehensive Cancer Center 4 days
New Technology to Streamline Drug Discovery
New Technology to Streamline Drug Discovery
Category: Other
5 Views
Cancer-News 5 days
Using Technology to Better Understand What Goes Wrong in Cancer
Using Technology to Better Understand What Goes Wrong in Cancer
Category: Breast Cancer
15 Views
Cancer-News 5 days